Opioid Use Disorder (OUD) Market to Reach USD 7.48 billion by 2032; Increasing Engagement by Governmental & Non-governmental Institutions to Foster Growth

The global Opioid Use Disorder (OUD) market size was valued at USD 3.35 billion in 2023. The market is projected to grow from USD 3.62 billion in 2024 to USD 7.48 billion by 2032, exhibiting a CAGR of 9.5% during the forecast period. The surge is on account of the growing implementation of regulatory policies. The treatment comprises three drug classes, naltrexone, methadone, and buprenorphine.

This information is presented by Fortune Business Insights, in its report titled, “Opioid Use Disorder (OUD) Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Buprenorphine, Methadone, and Naltrexone), By Route of Administration (Oral and Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Stores, and Online Pharmacies), and Regional Forecast, 2024-2032.”

The amount of prescriptions for painkillers, which frequently contain opioids, is likely to rise as the number of people experiencing chronic pain increases globally. However, when these opioid-based painkillers are consumed and the patient's discomfort subsides, the dependency or addiction to these drugs grows. Since an opioid overdose can result in death or a lifelong impairment of a person's normal psychological and physiological functioning, this addiction has lethal implications.

Reduced Demand for Medications amid COVID-19 Pandemic to Negatively Impact Market Growth

Depending on demand, the coronavirus pandemic's effects on the pharmaceutical industry have ranged from good to negative. Due to a drop in demand brought on by fewer visits to healthcare institutions, such as hospitals and clinics, there has been a negative effect on several pharmaceuticals. Many governments have also instituted severe nationwide lockdowns in an effort to reduce the number of coronavirus cases. The flow of patients between hospital settings has significantly decreased as a result of this. Further hindering the global Opioid Use Disorder (OUD) market growth, operations of non-essential medical treatment were cancelled or postponed.

Braeburn Receives Complete Response Letter for the NDA for BRIXADI

With relation to the New Drug Application (NDA) for Buprenorphine Extended-Release Injection (BRIXADI) for subcutaneous (SC) usage (CIII) for the treatment of moderate to severe OUD, Braeburn reports that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL). The FDA claimed in the CRL that problems discovered during a recent inspection at a third-party manufacturing site prevented it from approving the NDA.

Increasing Engagement by Governmental & Non-governmental Institutions to Aid Growth

The growing engagement of governmental and non-governmental organizations is another important driving force that is anticipated to enhance the OUD market growth throughout the forecast period. The number of people who are addicted to opioids has significantly increased, and this has prompted numerous governments to take a more extensive approach to address the pandemic. Nations have stepped up their efforts to assist patients and lessen the impact of opioid dependence.

The negative effects that could result from the medications used to treat opioid addiction are one of the most important restraints that are projected to restrict the growth of the global market during the forecast period.

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/opioid-use-disorder-oud-market-102674

Competitive Landscape

Partnerships among Companies to Secure their Brand Values in Global Market

Prominent players in the market are constantly opting for effective strategies to promote their products and establish their positions in the market. One such strategy is to launch new products by partnering with other companies to extend their reach to end-users. For instance, in December 2020, Orexo AB inked an agreement with Accord Healthcare for commercializing ZUBSOLV in Europe.

Notable Industry Development

• February 2021: To do additional study on the use of Modia, Orexo AB announced a partnership with ApexB.io and Magellan Rx Management. This digital therapy is a product made for people with Opioid Use Disorder.

List of Key Players Covered in the Report

• Indivior PLC (U.S.)


• Alkermes (Ireland)


• Orexo AB (Sweden)


• Titan Pharmaceuticals, Inc. (U.S.)


• Mallinckrodt Pharmaceuticals (U.K.)


• BioDelivery Sciences International Inc. (U.S.)


• Viatris Inc. (Mylan N.V.) (U.S.)


• Hikma Pharmaceuticals PLC (U.K.)


• Camurus (Sweden)

Further Report Findings

• North America stood at USD 2.39 billion in 2022, and is anticipated to be dominant during the forecast period owing to the substantial number of individuals in the U.S. suffering from opioid dependency, presence of prominent players in the region, and increasing involvement of the governments in tackling the pandemic.


• Based on drug class, the market includes buprenorphine, methadone, and naltrexone. The buprenorphine segment accounted for the largest Opioid Use Disorder (OUD) market share in 2022.

Table of Segmentation